Xin Lang Cai Jing·2025-10-20 03:09Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical's stock has seen a significant increase, with a 5.07% rise on October 20, reaching a price of 36.65 yuan per share, and a total market capitalization of 585.69 billion yuan [1] - Kelun Pharmaceutical has experienced a continuous stock price increase for three consecutive days, with a cumulative increase of 2.56% during this period [1] - The company, founded on May 29, 2002, and listed on June 3, 2010, specializes in the development, production, and sales of large-volume infusion products, with its main business revenue composition being 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from research projects, and 3.33% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Guotai Haitong Asset Management has a significant position in Kelun Pharmaceutical, specifically the Guotai Junan Innovative Medicine Mixed Fund A (014157), which reduced its holdings by 20,000 shares in the second quarter, now holding 212,200 shares, accounting for 5.06% of the fund's net value [2] - The fund has generated a floating profit of approximately 375,600 yuan today, with a floating profit of 184,600 yuan during the three-day stock price increase [2] - The Guotai Junan Innovative Medicine Mixed Fund A was established on December 23, 2021, with a current scale of 107 million yuan, and has achieved a year-to-date return of 19.4%, ranking 4019 out of 8234 in its category [2]